Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | The history of biomarkers in the treatment of prostate cancer

Howard Scher, MD, FASCO, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses biomarkers associated with poor outcome in prostate cancer at ASCO GU 2021. Dr Scher outlines challenges in response monitoring associated with bone metastases. Current response measures include changes in prostate-specific antigen (PSA). Dr Scher gives an overview of how circulating tumor cells (CTCs), which are present in blood, offer a novel biomarker for response monitoring in prostate cancer. This interview took place during the 2021 Genitourinary Cancers Symposium.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.